China to India: Formoterol Import Trade Route

The China to India Formoterol corridor is one of India's established pharmaceutical import routes from China, with 1 shipments documented worth a combined $1.7K USD. The route is dominated by CIPLA (CHINA) PHARMACEUTICAL CO LTD, which alone accounts for roughly 100% of all import value, reflecting the consolidated nature of China's formoterol export sector.

Across 1 active China suppliers, the average shipment value stands at $1.7K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (68%) and air (17%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.

Shipment activity peaks during October–December, with an average transit time of 16 days port-to-port. The route has recorded an annual growth rate of 28.3%, placing it at rank #8 among India's top formoterol import origins globally.

On the Indian buyer side, key Indian importers include CIPLA LIMITED. CIPLA LIMITED is the single largest Indian importer with 1 shipments valued at $1.7K USD.

India's formoterol imports from China are driven primarily by a handful of large-scale China manufacturers. CIPLA (CHINA) PHARMACEUTICAL CO LTD with 1 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 1 active exporters signals a competitive but concentrated market — Indian buyers benefit from China supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — CIPLA (CHINA) PHARMACEUTICAL CO LTD — together account for 100% of total trade value on this route. The average shipment value of $1.7K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

On the buying side, CIPLA LIMITED is the largest importer with 1 shipments worth $1.7K USD — representing 100% of all formoterol imports from China on this route.